Phase 2 Trial of Ruxolitinib Decitabine Combination for Blast-Phase Myeloproliferative Neoplasms
Clinical trial evidence evaluates combination targeted-agent regimens (a JAK inhibitor paired with a hypomethylating agent) as treatment for advanced-phase myeloproliferative neoplasms, assessing tolerability, response rate, and survival relative to conventional induction chemotherapy. This belongs to the field of hematology-oncology, specifically phase II clinical trial methodology for myeloid malignancies, where efficacy is measured through composite response rates and adverse-event profiles rather than cure.
Phase 2 Trial of Ruxolitinib Decitabine Combination for Blast-Phase Myeloproliferative Neoplasms
Clinical trial evidence evaluates combination targeted-agent regimens (a JAK inhibitor paired with a hypomethylating agent) as treatment for advanced-phase myeloproliferative neoplasms, assessing tol…